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Abstract (250 words)

BACKGROUND
There has been growing interest in early intervention in psychotic disorders. However,
gender differences in the outcomes of treatment have not been \studied in a clinical trial.
METHODS
Patients diagnosed with schizophrenia or schizoaffective disorder with less than 6 months
exposure to antipsychotics entered a cluster randomized trial of coordinated specialty
care in the Recovery After an Initial Schizophrenia Episode Early Treatment Program
(RAISE-ETP). Secondary analyses examined gender differences in baseline
characteristics as well as two-year gender outcomes, and the response to treatment
controlling for baseline differences. Blinded evaluators assessed the Quality of Life Scale
and the Positive and Negative Syndrome Scale (PANSS) every 6 months.
RESULTS
Altogether 404 individuals aged 15-40 entered the study, of whom 111 (27.4%) were
female and 293 (72.5%) were male. At baseline, women were significantly more likely to
have been married (p=0.007) and to be living independently (p=0.012) than men. Women
were also more likely to be diagnosed with schizoaffective disorder, bipolar type
(p=0.006) and scored higher on the depression subscale of the PANSS (p=0.0004).
Women were less likely to use or abuse cannabis (p=0.0004), though no less likely to use
or abuse alcohol. Controlling for these differences, there were no significant gender
differences in outcomes or response to treatment.
CONCLUSION
Baseline gender differences in comorbid substance use and prevalence of mood
symptoms in women with FEP are consistent with previous studies. The absence of
significant gender differences in outcomes or response to treatment has not been
previously established in a multi-site trial.
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INTRODUCTION

Disease Presentation by Gender and Diagnosis
There has been increasing interest in biological and psychosocial differences
between women and men in the clinical presentation, course of illness, and treatment
outcomes of mental disorders and specifically in psychotic disorders such as
schizophrenia. 1 Recent studies suggest that women with psychotic disorders are more
likely to present with positive and affective symptoms while men have more prominent
negative symptoms and cognitive impairments, 2 3 4 and are more likely to meet criteria
for comorbid substance use disorders. 2 Female patients have been found to experience a
pre-psychotic prodrome for twice as long as male patients, 5 and, perhaps as a result,
experience full psychotic disorders at later age. 6 They also experience less impaired
social functioning 7, while longitudinally, it has been suggested that women respond more
quickly and completely to available treatments, with greater likelihood of remission and
lower relapse rates. 6 While short-term studies suggest better quality of life among
women with psychotic disorders than men, 7 longer term studies suggest these differences
dissipate over time. 8

Initial Treatment
The mainstay of treatment for psychotic spectrum disorder is symptomatic
treatment with antipsychotics. There is a preference for second-generation antipsychotics
due to fewer extrapyramidal symptoms associated with second-generation
antipsychotics.9 After initiating treatment, antipsychotics are titrated to therapeutic dose
as tolerated.
Agent

Initial oral dose range

Usual oral dose

Usual maximum

(mg/day)

range (mg/day)

oral dose
(mg/day)

Aripiprazole 10 to 15

10 to 15

30

Clozapine

25 to 50

150 to 600

900

Olanzapine

5 to 10

10 to 20

30

Quetiapine

50 (immediate release)

400 to 800

800

2 to 6

8

300 (extended release)
Risperidone

1 to 2

Supplemental Table 1: Initial Dosing and Titration of Selected Second-Generation Antipsychotics 10
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Maintenance Treatment
If patient has responded fully and is no longer psychotic, antipsychotics are
continued for two to three years if there is high suspicion for schizophrenia. Weekly
follow-up is recommended for first three months of treatment for clinical evaluation of
medication efficacy as well as monitoring of possible adverse effects including
extrapyramidal symptoms (e.g. akathisia, parkinsonism, tardive dyskinesia), orthostasis,
metabolic dysregulation (e.g. insulin resistance, weight gain), and QT elongation.
If patient has a partial response or recurrence of symptoms, assessing for
compliance is important. Antipsychotics have a range of side effects that may
significantly impact quality of life and may lead to medication noncompliance. If patient
has had an adequate trial of the antipsychotic at therapeutic range, a change in
antipsychotic is indicated. The decision is usually patient-centered, considering side
effect profiles.
If patient continues to be symptomatic after two or more antipsychotics, the
patient is considered to have treatment-resistant schizophrenia, and clozapine is indicated.
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Study Purpose and Goals
Among the most important recent developments in the treatment of schizophrenia
has been growing evidence that comprehensive coordinated specialty care can have
important positive impact on outcomes on when provided early in course of the illness. 11
However, only two studies have focused specifically on differences between women and
men in their first episode of psychosis (FEP). 3 4These studies, one on an Italian and the
other on a Swiss FEP sample, largely confirmed previous baseline findings showing that
women showed higher levels of affective symptoms and men, more severe negative
symptoms. Female patients also showed greater insight into their illness with higher
levels of functioning but more unmet needs. To our knowledge, no studies have looked at
gender differences in the delivery and outcomes of coordinated specialty care for FEP in
the U.S..
The recent National Institute of Mental Health (NIMH)-funded Recovery After an
Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) study, a 34 site
cluster randomized trial of early episode psychosis in real-world settings (n=404), found
comprehensive coordinated care improved quality of life, reduced symptoms 12 and
increased school and work involvement 13 as compared to usual community care.
Interaction analyses have shown greater improvement in those with shorter duration of
untreated psychosi life s (Kane 2016) or higher socio-economic status (Bennett and
Rosenheck, 2020). However, a secondary analysis comparing female and male
participants has yet to be conducted. In this paper, we use data available from the RAISEETP trial, to compare women and men on baseline characteristics, use of services, and
two-year outcomes.

8

9

Hypothesis
Literature review suggest that men have worse baseline functioning, less insight,
poorer quality of life and slower antipsychotic response than women. My hypothesis is
that men will benefit more from early intervention given their lower baseline functioning
at FEP.

10

STATEMENT OF PURPOSE

To determine gender differences in outcomes of the RAISE-ETP trial.
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METHODS

Student Contributions
Student completed a thorough literature review on existing literature on the effect
of gender on psychotic spectrum disorders and of outcomes in psychiatric and medical
illnesses. This ad hoc analysis did not require generation of data. Statistical analysis of
public access data, available from the National Institute of Mental Health was conducted
by collaborator Dr. Daniel Bennett and Dr. Robert Rosenheck. Student, with the help of
Dr. Rosenheck, created relevant figures and tables, and interpreted the findings in context
of larger literature on gender-specific outcomes in mental illness and other areas of
medicine.

12

Ethics Statement
Previous studies have included details on the recruitment process including a
CONSORT diagram of recruitment and disposition, 12 and an extensive description of the
clinical intervention, called NAVIGATE 14.
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Methods Description
Subjects and Sites
Inclusion criteria included: presenting for first episode of psychosis, exposure to
antipsychotic medication for fewer than 6 months, and enrollment between July 2010 and
July 2012. In total, 404 individuals aged 15-40 entered the study, of whom of whom 111
(27.4%) were female and 293 (72.5%) were male. Written informed consent was
obtained from adult participants or from legal guardians for those under 18 years old. The
Institutional Review Boards of the coordinating center and at each site approved the
study. An NIMH Data and Safety Monitoring Board provided oversight to the original
study. Thirty-four community mental health treatment centers across the United States
were randomized to either to a specialized coordinated intervention called NAVIGATE
or to usual community care.

Intervention
NAVIGATE coordinated care included: a) a web-based decision support system
for assisting personalized medication management; b) family psycho-education; c)
individual, resilience-focused training in illness self-management; and d) supported
employment and education via remote training and consultation. 14 Participants without
initial interest in work or school received continuing encouragement to participate in
supported employment and education. At 13 of 17 NAVIGATE sites, patients received at
least twice a month contact with employment and education specialists. The mean
caseload was 10.72 clients for every employment and education specialist. The patient
rating of support for employment and education across 9 fidelity items found that 4 sites
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were rated between upper range of basic to good, 11 sites rated lower range of basic to
good, and 2 sites were limited in fidelity. [12]

Assessments
Blinded evaluators remotely assessed quality of life and symptoms (see measures,
below) at baseline and every 6 months for two years via videoconferencing. Self-report
rating scale assessments were obtained at the same interval.
Self-report data on socio-demographic characteristics were recorded at baseline.
Independent research assistants gathered additional data through monthly patient
interviews. These interviews measured service use and employment on a monthly basis
and self-reported well-being and sources of income (including disability payments) every
three months.

Measures
Initial assessment included documentation of socio-demographic characteristics. A
central team of blinded evaluators assessed quality of life using the Quality of Life Scale
(QLS) 15 with 4 subscales of interpersonal relationships, instrumental role functioning,
intrapsychic foundations (more recently re-conceptualized as “motivation”), and common
objects and activities used in daily life. Psychiatric symptom severity was measured with
the Positive and Negative Syndrome Scale (PANSS) 16 with five subscales 17 and the
Calgary Depression Scale for Schizophrenia (CDSS). 18
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Patients self-reported well-being was assessed using a reduced versions of the
perceived well-being scale 19, the Mental Health Recovery Measure, 20 the Autonomy
Support Scale-Short Form, 21 the Brief Evaluation of Medication Influences and Beliefs,
22

and the Stigma Scale. 23
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Statistical Methods
Baseline characteristics were compared between genders using linear regression
with interactions between round dummies and gender.
All standard errors in the longitudinal regressions were clustered by site to
account for arbitrary error correlations within a site, including across individuals over
time. All regressions controlled for baseline marital status, current residence, diagnosis,
cannabis use, previous hospitalizations, age, and baseline depression symptoms because
these variables were shown to be imbalanced by gender at baseline.
Longitudinal analyses of gender differences included terms representing gender,
time in months since the baseline (a single continuous variable) and the interaction of
gender by time.
Longitudinal analyses of gender differences in treatment effects included main
effects for gender, time, and treatment; the interaction of gender by time and treatment by
time; and the term of interest, the three-way interaction of gender by time by treatment.
Subscales were examined only for the primary outcome, the QLS, to avoid artifactual
results from multiple comparisons.
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RESULTS
Baseline Characteristics
A total of 111 (27.4%) female patients and 293 (72.5%) male patients were
included in the study. Mean age of female patients at first episode psychosis was
significantly older at 24.33 ± 6.19 years compared to 22.68 ± 4.5 years of male patients
(p = 0.0067) (Table 1).
Of the female patients, 89 (80.2%) were never married, compared to 269 (91.8%)
of male patients (p=0.007) (Table 1). A total of 31 (27.9%) female patients lived
independently and 72 (64.9%) lived with family members including parents,
grandparents, and siblings. In comparison, only 41 (14.0%) of male patients lived
independently and 215 (73.4%) lived with family. Females patients were significantly
more likely to have been married (p=0.007) and significantly more likely to be living
independently (p=0.012) compared to male patients.
A total of 44 female patients (40%) were covered by public insurance compared
to 83 (28.5%) male patients (p=0.03).
There were no significant gender differences in race/ethnicity, patient education
and employment status, or parental education status (Table 1).
In diagnosis across the psychotic disorder spectrum a great proportion of women
than men (14 women, 12.6% and 10 (3.4%) men) were diagnosed with schizoaffective
disorder, bipolar type (p=0.006).
Turning to substance abuse or dependence, women were overall less likely to use
or abuse drugs of any type with only 24 (28.8%) female patients meeting abuse or
dependence criteria for lifetime cannabis use, compared to 116 (39.6%) male patients
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(p=0.0023). There were no significant gender differences in lifetime alcohol abuse or
dependence. Recent use of illegal drugs including cannabis also was significantly
different across genders with women using drugs on an average of 1.55 ± 5.33 days of the
30 days prior to enrollment, significantly few days than men who used drugs on an
average of 3.74 ± 8.07 days (p=0.008).
There were also significant gender differences in number of hospitalizations prior
to enrollment in the study. Among female patients 5 (6.2%) were hospitalized twice and 6
(7.4%) were hospitalized three times or more prior to enrollment. In contrast, only 9 male
patients (3.8%) were hospitalized twice and only 12 (5.0%) were hospitalized three or
more times prior to enrollment. Overall, women were significantly more thus likely to
have been hospitalized multiple times prior to FEP (p=0.0087) (Table 2).
There were no significant gender differences on measures of medication
compliance or duration of untreated psychosis.

On the Heinrich Carpenter measure of Quality of Life Interview women scored
significantly higher than men (p=0.02) (Table 3). Specifically, women averaged higher
on on the interpersonal relations and the common objects and activities subscales (Table
3). There were no differences within the instrumental role subscale and intrapsychic
foundations subscale.
On the PANSS symptom severity scale, women scored significantly higher
(p=0.0004) on the depression subscale (Table 3). There were no significant gender
differences on the total PANSS score or on other subscales of the PANSS (positive,
negative, disorganized/concrete, and excited). There were also no significant differences
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in CDSS, a specific depression symptom severity scale, although women had nonsignificantly higher scores (p=0.15).

There were no further gender differences in other self-reported social and wellbeing measures such perceived well-being scale, the Mental Health Recovery Measure,
the Autonomy Support Scale-Short Form, the Brief Evaluation of Medication Influences
and Beliefs score, and the Stigma Scale score.
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Longitudinal Analyses
Longitudinal analyses examining differences in outcomes by gender (i.e. the
interaction of gender by time) showed no significant differences on the primary outcomes
of QLS or on total PANSS symptoms (Table 4, column 3) but did show a significantly
greater improvement in the intrapsychic functioning sub-scale of the QOLI among
women (p<.05).
Evaluation of differences in treatment effects by gender (interaction of gender by
time and by treatment group) showed no significant differences on any measure of
clinical outcome or NAVIGATE service use (Table 4, column 4).

21
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DISCUSSION

Secondary analysis of RAISE-ETP data on patients with early episode psychosis
revealed that at program entry women were older with higher QLS scores and better
social functioning than men, characteristics that are consistent with previous literature. 6
They also had more severe mood symptoms, 2 more numerous psychiatric
hospitalizations and reported less use of cannabis but not alcohol or other drugs.
Longitudinal analyses, the primary focus of this study, showed that controlling for these
admission differences, there were no significant gender differences in 2-year measures of
quality of life, in schizophrenia or depressive symptoms; or in use of key components of
the coordinated specialty care intervention. Furthermore, no gender differences were
observed in response to treatment over follow-up of 2 years.
Previous research on gender and schizophrenia suggests that women fare better
than men early in the disease course, possibly due to their older age at onset and better
adherence and response to antipsychotic medications, 7 though one study showed this
advantage fades over time. 8
A review of the literature on the association of gender and treatment outcomes in
other mental illnesses reveal mixed findings. A review of Post-Traumatic Stress Disorder
(PTSD) treatment outcome studies found equivocal effects of gender. 24 More
specifically, studies comparing outcomes of exposure-only therapy and exposure-therapy
plus cognitive restructuring therapy for PTSD, also found no gender effects 25,26 as did a
refugee population receiving cognitive restructuring therapy. 27 A longitudinal follow-up
of hospitalized adult patients with a history of childhood abuse similarly found no gender
differences in outcomes 28 but a large multi-site study from the Veterans Health
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Administration reported greater reduction in PTSD symptom scores among female than
male Veterans. 29 This finding of superior outcomes for women diagnosed with PTSD
patients has been reported in both additional VA 30 a non-VA samples. 31,32
In the realm of substance use disorders, a review of 126 efficacy and effectiveness
trials for nicotine dependence found that only two trials showed women to be
significantly more likely to quit smoking than men, while 59 found women were
significantly less likely to quit smoking. In addition, when followed for longer duration
of time, women were particularly less likely to quit smoking than men. 33
In the treatment of opioid use disorder women appear to do better than men on
measures of both retention in treatment and relapse to drug use. Weinstein and
colleagues, for example, reported women were 55% more likely to remain in treatment
than men 34 and a seven-year follow-up study found that women had both greater
treatment retention and employment and lower relapse rates than men. 35 Hser and
colleagues identified young men who are daily drug users, unemployed, and unmarried as
the highest risk group for dropping out of methadone maintenance but did not explicitly
compare women and men. 36 More simply, Levine and colleagues reported no association
of gender with retention rate in medication assisted treatment for drug abuse although a
sub-group of women who had negative first month cocaine and marijuana urine tests and
no history of sexual victimization were more likely to remain in treatment. 37
Looking at other psychiatric conditions, Cuijpers and colleagues reported no
gender effect on depression outcome after CBT and pharmacotherapy 38 and a general
review found no gender effect on short- and long-term outcome in anorexia nervosa. 39
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There are similarly mixed effects of gender on the few studies of outcomes of
treatment for medical illnesses. Carcel and colleagues reported that, compared to men,
women with ischemic but not hemorrhagic stroke had lower 3- to 6-month mortality
when exposed to diverse treatments. However, women were more likely to be disabled
and had worse quality of life on the EuroQOL 5-Dimension self-report questionnaire of
quality of life. 40
A pooled analysis of randomized, controlled trials evaluating effectiveness of
insulin in diabetes found that women had smaller reductions in HbA1c and were less
likely to reach glycemic goals despite higher insulin doses and had more hypoglycemic
events than males. 41 A post hoc analysis of a randomized, controlled trial evaluating the
effect of berberine and pioglitazone on glucose metabolism in nonalcoholic fatty liver
disease also reported greater benefits for women than for men. 42
This unsystematic overview of differences in gender outcomes in other mental
health disorders and some medical conditions showed no consistent pattern of gender
differences in outcomes in the published literature with many no-difference findings like
those observed in this study of outcomes and response to treatment in early episode
schizophrenia.
Future research should focus further on longitudinal outcomes of FEP patients
using larger samples sizes in longitudinal analysis. In addition, special attention might be
brought to perimenopausal women. Perimenopause is an established period of
vulnerability in psychotic spectrum illnesses, and is speculated to be secondary to loss of
protective effect of estrogen (CITATION).
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Limitations
Several methodological limitations require comment. First gender comparisons
inevitably require observational research designs since random assignment is not
possible. As a result. there may be unmeasured factors that influence outcomes
differently among women and men. Since we found no evidence of gender differences in
outcomes, after controlling for baseline differences that were measured, it seems unlikely
that such factors would have altered our main findings. Second the study was not
specifically designed to examine gender interactions affecting outcomes and may not
have been adequately powered, especially in view of the fact that the sample of women
was smaller than that of men. However, the fact that significant interactions have been
found in other secondary analyses of the duration of untreated psychosis 12 and social
class 43 suggests that the sample was adequate for identifying significant interactions if
they existed. Third, although the study was conducted at 34 sites across the US the
representativeness of the sample is unknown and thus the generalizability of the results is
uncertain.
There is also larger limitation in medical science at large, which is the historical
and current structural exclusion of women in research. In this thesis, women were the
centered to be the main subject of interest. Historically, androcentrism in science has
considered male bodies to be the “default” human body. This bias is visible in every
aspect of medicine and medical education—from the regular practice of learning CPR on
only male mannequins to the exclusion of pregnant or possibly pregnant women in
pharmacological trials. Pregnant women are considered a vulnerable population, and
excluding women of reproductive age might be seen as a solution to ethical challenges.
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However, women are not smaller men.
Thorough review of literature shows that there are specific gender differences in
epidemiological characteristics of psychiatric and medical illnesses. In limited
incidences, specific drugs might be more efficacious in women. What might our
healthcare look like if we regularly center women in making scientific advancements?
Another point of interest is the intersection of biological sex and socially
influenced gender. RAISE-ETP trial only collected self-identified demographic data, thus
limiting data on biological sex. As a result, we are unable to specifically comment on
whether sex/gender incongruence and its effect on outcomes. We expect statistical
analysis to be same with and without sex/gender data, as transgender and gender nonbinary adults are a small minority. Thus, whatever differences that may have been can be
considered outliers in statistical analysis.
However, this is an important learning point. As we gather data, routine practice
of collecting both sex and gender will make gender analysis more inclusive of trans and
gender non-conforming patients. In fact, given the high comorbidity of depression and
other mental health illnesses in the transgender population, there might be a pressing need
to collect more granular data to include transgender and gender non-conforming identity
as a possible variable in analysis.
We must touch on the difference of biological sex and sociological experience of
gender. Sex, or the biological differences in the continuum of male and female, does
present real biochemical ramifications. The effect of sex hormones on human behavior,
immune system, and manifestations of psychiatric illnesses are well established. Gender,
or the social experience of men and women, is culturally specific. From an early age,
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children are taught different gender roles, and girls are socialized very differently from
boys. Given the well-established effect of chronic stress on health, we must consider the
role of sexism in interpretation of gender differences.
The above, however, is less relevant for this paper, given findings of no
differences.

28

CONCLUSION

Secondary analysis of the RAISE-ETP trial found at baseline women were older,
less likely to use or abuse cannabis but not alcohol, had more mood-associated
symptoms, higher quality of life, and more past hospital use. Adjusting for baseline
differences, there were no significant effects of gender on the primary outcome of quality
of life, total schizophrenia symptoms, or use of Coordinated Specialty Care services.
Benefits of the NAVIGATE intervention as compared to usual community care also did
not differ significantly by gender.
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Figure 1: PAANS Score by Treatment Group and Gender.

Figure 2: QoL Score by Treatment Group and Gender
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Table 1. Sociodemographic Characteristics by Gender at program entry.
N (%)

Male

Female

(n=293)

(n=111)

22.68 (4.5)

1

24.33 (6.19)

52 (46.9%)

p-

0.006
7

F=1.37

Race
166

df

value

t=2.73

Age^

White

F or t

2

0.16

F=1.24

1

0.27

F=7.42

1

0.006

F=1.99

(56.7%)
Non-white

127

59 (53.2%)

(43.3%)
Hispanic ethnicity

59 (20.1%)

14 (12.6%)

Marital status

8
Presently married

13 (4.4%)

11 (9.9%)

Widowed/divorced/se

11 (3.8%)

11 (9.9%)

269

89 (80.2%)

parated
Never married

2

(91.8%)
F=4.48

Current residence

1

0.011
9

Independent living

41 (14.0%)

31 (27.9%)

31

Supported or

12 (4.1%)

2 (1.8%)

215

72 (64.9%)

structured
Family, parents,
grandparents, sibling

(73.4%)

Homeless, shelter, or

25 (8.5%)

6 (5.4%)

other
F=2.37

Patient’s education

2

0.094
5

Some college or

83 (28.3%)

42 (37.8%)

102

31 (27.9%)

higher
Completed high
school

(34.8%)

Some high school

93 (31.7%)

32 (28.8%)

Some or completed

15 (5.1%)

6 (5.4%)

grade school
F=1.75

Mother’s education
Some college or
higher
Completed high

130

37 (33.3%)

(44.4%)
79 (27.0%)

32 (28.8%)

34 (11.6%)

25 (22.5%)

school
Some high school or
grade school

32

2

0.17

No school or

50 (17.1%)

1(15.3%)

unknown
F=3.41

Type of insurance

2

0.034
1

Private

68 (23.4%)

14 (12.7%)

Public

83 (28.5%)

44 (40.0%)

140

52 (47.3%)

Uninsured

(48.1%)
^Continuous variable. Unmarked variables are categorical variables .
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Table 2. Community Adjustment and Quality of Life by Gender at program entry.
N (%)

Male

Female

(n=293)

(n=111)

F or t

df

pvalue

Current Student

56 (19.1%)

26 (23.4%) F=0.78

1

Currently working

42 (14.3%)

16 (14.4%) F=0.09

1

0.76

Student or working

86 (29.6%)

36 (32.7%) F=0.16

1

0.69

t=2.25

1

Quality of Life^
Total score

Interpersonal relations

Instrumental role
Intrapsychic foundations

51.25

56.28

0.024

(18.54)

(18.96)

9

19.26

21.08

(8.84)

(8.18)

5.14 (6.3)

6.69 (7)

20.49
(6.92)

6.81 (2.12)

t=0.15

5.53 (1.15)

t=0.04

0.048

87

7

0.77
1

4.85 (1.05)

0.45
t=1.53

Mental health recovery
measure mean score^

4.96 (1.16)

4.74 (1.42)

Stigma scale mean score^

3.95 (1.15)

4.09 (1.27)

34

1

5.58 (1.38)
t=0.75

4.95 (1.01)

0.15

0.12

t=0.3

BEMIB (medication influence
and beliefs) mean score^

7

21.7 (7.08)

Autonomy support scale mean
score^

0.053

t=0.12

Common objects and activities
6.36 (2.37)

t=1.94

1
0.13

t=0.94

1

0.35

4.01 (0.77)

3.89 (0.86)

t=1.25

1

63.43

58.78

t=0.13

1

(23.21)

(24.53)

Life as a whole^

4.41 (1.41)

4.18 (1.45)

t=1.18

1

0.24

Intent to complete^

7.51 (1.68)

7.33 (2.02)

t=1.07

1

0.29

Intent to attend next visit^

7.98 (1.54)

7.97 (1.75)

t=0.26

1

0.80

Well-being scale mean score^
Current state of MH^

0.13

^Continuous variable. Unmarked variables are categorical variables.
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0.21

Table 3. Clinical Characteristics
N (%)

Male

Female

(n=293)

(n=111)

SCID diagnoses
Schizophrenia

162

t or F

df

pvalue

F=3.58

4

0.0059

F=3.36

1

0.0676

F=9.39

1

0.0023

52 (46.9%)

(55.3%)
Schizoaffective bipolar

10 (3.4%)

14 (12.6%)

Schizoaffective depressive

36 (12.3%)

21 (18.9%)

Schizophreniform provisional or

52 (17.8%)

15 (13.5%)

33 (11.3%)

9 (8.1%)

definite
Brief psychotic disorder
Lifetime alcohol use disorder
Did not meet criteria

178

79 (71.2%)

(60.8%)
Met abuse or dependence criteria

115

32 (28.8%)

(39.3%)
Lifetime cannabis use disorder
Did not meet criteria

177

87 (78.4%)

(60.4%)
Met abuse or dependence criteria

116

24 (21.6%)

(39.6%)
1

Number of days of alcohol
intoxication^

0.4 (2.08)

36

0.78 (2.87)

0.15

Number of days of illegal drugs^

3.74 (8.07)

1.55 (5.33)

Duration of untreated psychosis

191.06

199.97

(254.96)

(281.48)

(weeks)^
Number of prior hospitalizations
0

200

1
t=0.3

0.0078

1
0.76

F=3.94

3

0.0087

F=3.4

1

0.0661

F=1.67

2

0.19

F=0.62

1

0.43

67 (82.7%)

(83.7%)
1

18 (7.5%)

3 (3.7%)

2

9 (3.8%)

5 (6.2%)

3 or more

12 (5.0%)

6 (7.4%)

Prescribed one or more

251

86 (77.5%)

antipsychotics at consent

(85.7%)

Days not taking first antipsychotic
Few if any, <7

200

67 (60.4%)

(68.7%)
7 or more

39 (13.4%)

14 (12.6%)

Not prescribed antipsychotic

52 (17.9%)

30 (27.0%)

Days taking less than prescribed
number of pills
Never or almost never, 0 to 25%

202

64 (57.7%)

(69.4%)
Sometimes to always, 26 to 100%

37 (12.7%)

17 (15.3%)

Not prescribed antipsychotic

52 (17.9%)

30 (27.0%)

37

Duration of lifetime anti-psychotic
medication at consent (days)^

43.95

44.54

(43.95)

(50.6)

0.89
1

PANSS Symptom severity^
Total score

76.82

76.1

(14.72)

(15.82)

t=0.76
0.76

Factor scores
Positive

12.25

t=0.5

(3.91)

12.2 (3.64)

16.98

15.94

(5.14)

(5.22)

Disorganized/concrete

7.96 (2.68)

7.41 (2.99)

t=1.57

0.12

Excited

6.77 (2.83)

6.68 (2.58)

t=0.24

0.81

Depressed

7.69 (3.22)

9.01 (3.37)

t=3.57

0.0004

CDSS^

4.46 (4.35)

5.16 (4.06)

t=1.44

1

0.15

CGI^

4.04 (0.81)

4.06 (0.85)

t=0.28

1

0.78

Negative

^Continuous variable. Unmarked variables are categorical variables.

38

0.96
t=1.72
0.09

Table 4. Longitudinal outcomes of women and men in the RAISE-ETP program and
differential response to NAVIGATE treatment
Interaction of Female
Outcome or Treatment
Measure

N

Interaction of

by time by treatment

Female by time^

group #

Quality of Life Scale (Total
1373

Score)
(se)
Interpersonal Relations

1376

(se)
Intrapsychic functioning

1374

(se)

0.0842

-0.0171

(0.1080)

(0.2400)

0.0289

-0.0175

(0.0507)

(0.1180)

0.0721*

-0.0238

(0.0322)

(0.0659)

-0.0237

0.0396

(0.0472)

(0.0846)

0.0077

-0.0070

(0.0139)

(0.0243)

0.0462

0.1200

(0.0914)

(0.2100)

0.0216

-0.0397

(0.0201)

(0.0343)

Instrumental Role
Functioning

1375

(se)
Common objects and
Activities

1374
(se)

PANSS total score

1377

(se)
Calgary Depression Score

1377

(se)

39

Decision support for
1329

medications
(se)

0.0048

-0.0035

0.0385

0.0058

0.0024

-0.0003

(0.00241)

(0.0052)

-0.0002

0.0005

(0.00251)

(0.0036)

0.0012

0.0075

(0.0034)

(0.0049)

Supported
employment/education

1324

(se)
Family psychoeducation

1331

(se)
Individual resiliency training
participation

1331

(se)

+Adjusted for age, marital status, living situation, psychotic diagnoses, use of cannabis, use of
drugs, number of lifetime psychiatric hospitalizations, depressive symptoms and clustering of
observations between sites.
* p<.05
^ model includes terms for main effects of gender and time in addition to the interaction term.
# model includes terms for main effects of gender, time and treatment, interactions of time and
gender and time and treatment as well as the final three-way interaction term
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